JP7427585B2 - 多価ネコワクチン - Google Patents

多価ネコワクチン Download PDF

Info

Publication number
JP7427585B2
JP7427585B2 JP2020524411A JP2020524411A JP7427585B2 JP 7427585 B2 JP7427585 B2 JP 7427585B2 JP 2020524411 A JP2020524411 A JP 2020524411A JP 2020524411 A JP2020524411 A JP 2020524411A JP 7427585 B2 JP7427585 B2 JP 7427585B2
Authority
JP
Japan
Prior art keywords
fcv
feline
vaccine
virus
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506746A5 (enExample
JP2021506746A (ja
Inventor
シュ，ジーチャン
ラフルール，ロンダ
ターピー，イアン
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2021506746A publication Critical patent/JP2021506746A/ja
Publication of JP2021506746A5 publication Critical patent/JP2021506746A5/ja
Priority to JP2023158724A priority Critical patent/JP7742695B2/ja
Application granted granted Critical
Publication of JP7427585B2 publication Critical patent/JP7427585B2/ja
Priority to JP2025101576A priority patent/JP2025170230A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2020524411A 2017-12-15 2018-11-05 多価ネコワクチン Active JP7427585B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023158724A JP7742695B2 (ja) 2017-12-15 2023-09-22 多価ネコワクチン
JP2025101576A JP2025170230A (ja) 2017-12-15 2025-06-17 多価ネコワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599401P 2017-12-15 2017-12-15
US62/599,401 2017-12-15
PCT/EP2018/080106 WO2019115090A1 (en) 2017-12-15 2018-11-05 Multivalent feline vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023158724A Division JP7742695B2 (ja) 2017-12-15 2023-09-22 多価ネコワクチン

Publications (3)

Publication Number Publication Date
JP2021506746A JP2021506746A (ja) 2021-02-22
JP2021506746A5 JP2021506746A5 (enExample) 2021-05-06
JP7427585B2 true JP7427585B2 (ja) 2024-02-05

Family

ID=64316488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524411A Active JP7427585B2 (ja) 2017-12-15 2018-11-05 多価ネコワクチン
JP2023158724A Active JP7742695B2 (ja) 2017-12-15 2023-09-22 多価ネコワクチン
JP2025101576A Pending JP2025170230A (ja) 2017-12-15 2025-06-17 多価ネコワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023158724A Active JP7742695B2 (ja) 2017-12-15 2023-09-22 多価ネコワクチン
JP2025101576A Pending JP2025170230A (ja) 2017-12-15 2025-06-17 多価ネコワクチン

Country Status (4)

Country Link
JP (3) JP7427585B2 (enExample)
AU (2) AU2018383915B9 (enExample)
CA (1) CA3080087A1 (enExample)
WO (1) WO2019115090A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421790B2 (en) * 2015-12-23 2019-09-24 Intervet, Inc. Feline calicivirus vaccine
EP4149532A1 (en) 2020-05-11 2023-03-22 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
CA3198118A1 (en) 2020-11-12 2022-05-19 Martijn Alexander LANGEREIS Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527584A (ja) 2000-03-09 2003-09-16 ヘスカ コーポレイション 動物の免疫状態を決定するための組換え抗原の使用
JP2004507249A (ja) 2000-08-29 2004-03-11 ワイス・ホールディングズ・コーポレイション プラス鎖ｒｎａウイルスレプリコン粒子のパッケージング
JP2007537761A (ja) 2004-05-18 2007-12-27 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
JP2008512130A (ja) 2004-09-13 2008-04-24 ワイス 出血性ネコカリシウイルス、カリシウイルスワクチンおよびカリシウイルス感染または疾患を予防するための方法
WO2017109045A1 (en) 2015-12-23 2017-06-29 Intervet International B.V. Feline calicivirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309495B2 (en) 2003-03-14 2007-12-18 The Regents Of The University Of California Hemorrhagic feline calicivirus
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US10411152B2 (en) * 2016-06-27 2019-09-10 Merlin Solar Technologies, Inc. Solar cell bonding
CA3080427A1 (en) * 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine
AU2018380582B2 (en) * 2017-12-08 2025-08-14 Intervet International B.V. Feline calicivirus vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527584A (ja) 2000-03-09 2003-09-16 ヘスカ コーポレイション 動物の免疫状態を決定するための組換え抗原の使用
JP2004507249A (ja) 2000-08-29 2004-03-11 ワイス・ホールディングズ・コーポレイション プラス鎖ｒｎａウイルスレプリコン粒子のパッケージング
JP2007537761A (ja) 2004-05-18 2007-12-27 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
JP2008512130A (ja) 2004-09-13 2008-04-24 ワイス 出血性ネコカリシウイルス、カリシウイルスワクチンおよびカリシウイルス感染または疾患を予防するための方法
WO2017109045A1 (en) 2015-12-23 2017-06-29 Intervet International B.V. Feline calicivirus vaccine

Also Published As

Publication number Publication date
AU2022209359A1 (en) 2022-09-29
WO2019115090A1 (en) 2019-06-20
JP2021506746A (ja) 2021-02-22
JP2025170230A (ja) 2025-11-18
JP2023179547A (ja) 2023-12-19
CA3080087A1 (en) 2019-06-20
AU2018383915B2 (en) 2023-05-25
AU2018383915A1 (en) 2020-05-14
AU2018383915B9 (en) 2023-06-01
JP7742695B2 (ja) 2025-09-22
AU2022209359B2 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
JP7742695B2 (ja) 多価ネコワクチン
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
JP7714009B2 (ja) 狂犬病ウイルスワクチン
JP7721604B2 (ja) ネコカリシウイルスワクチン
US11730809B2 (en) Multivalent feline vaccine
US20240398934A1 (en) Feline leukemia virus vaccine
RU2797538C2 (ru) Поливалентная вакцина для животных семейства кошачьих
RU2792898C2 (ru) Вакцина против кошачьего калицивируса
RU2782350C2 (ru) Вакцина против вируса бешенства
RU2784533C2 (ru) Вакцина против вируса лейкоза кошачьих

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240124

R150 Certificate of patent or registration of utility model

Ref document number: 7427585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150